Guangdong Tiankeya Biopharmaceutical Technology

Tiankeya is a clinical-stage biotechnology company specializing in the development of T-cell receptor engineered T-cell (TCR-T) therapies for the treatment of solid tumors. Founded by experts in immunology and oncology, the company utilizes its proprietary TRUST platform for high-throughput TCR screening and its T-MAX technology for enhanced T-cell persistence and efficacy. Its lead programs target HPV-associated malignancies and NY-ESO-1 positive tumors, with several candidates currently in Phase 1 clinical trials in both China and the United States. Tiankeya maintains integrated capabilities across R&D, clinical development, and GMP manufacturing with facilities in Guangzhou, Suzhou, and the U.S.